Journal of Proteomics & Bioinformatics
Open Access

Predicting, avoiding and mitigating risk of failure when developing biotherapeutics

3^rd International Conference on Antibodies, Bio Therapeutics & B2B & Genetic and Protein Engineering

November 08-09, 2017 | Las Vegas, USA

Yvette Stallwood

Lonza Biologics, UK

Scientific Tracks Abstracts: J Proteomics Bioinform

Abstract :

This presentation will discuss how in silico and in vitro methodologies are employed to perform a developability and immunogenicity risk assessment in order to highlight potential risks of failure for the development of biotherapeutics. In silico methods can be used to evaluate protein sequence and structure to assess the likelihood of immunogenic responses and potential manufacturability issues including aggregation and PTMs. Ex vivo T and B-Cell responses enable the assessment of overall immunogenicity risks; different approaches are highlighted to further identify processed and presented epitopes.

Biography :

Yvette Stallwood has completed her PhD at the University of Birmingham (UK) and joined Lonza in 2007. She has been Head of Applied Protein Services for five years. The Applied Protein Services team are focussed on the development and provision of services to support the development of new biotherapeutic proteins with a particular focus on immunogenicity and manufacturability.